ADJUVANT THERAPY FOR BREAST CANCER STAGE I (HER-2 POSITIVE) : EXPERIENCE IN THE

Leonardo Villacres Montesdeoca; Mauricio Romero Mazon; Jonathan Freire Sosa; Mauricio Coral Proano; Jorge Acosta Parra; Andres Esp�n Puchaicela; Gabriel Loor; Rene Munoz

Volume : VIII, Issue : V, May - 2019

ADJUVANT THERAPY FOR BREAST CANCER STAGE I (HER-2 POSITIVE) : EXPERIENCE IN THE

Leonardo Villacres Montesdeoca, Mauricio Romero Mazon, Jonathan Freire Sosa, Mauricio Coral Proano, Jorge Acosta Parra, Andres Esp N Puchaicela, Gabriel Loor, Rene Munoz

Abstract :

Objectives: to describe the demographic variables of east cancer stage I HER-2 positive and to assess the response to adjuvant therapy with different protocols. Methods: A descriptive analysis of women over 18 years old treated with adjuvant chemotherapy with or without trastuzumab, assessing overall survival and the survival estimation was performed by Kaplan Meier method and comparated with Log Rank test. Results: Adjuvant therapy was performed in 22 patients stage I, IA (19 / 86.4%) and IB (3 / 13.6%), a global survival was reached until December 2018 of 65.5 months, however, according to the treatment, trastuzumab as monotherapy had a survival of 70 months, TCH=40 months, AC=76 months, AC-H=61.5 months, AC-TH=75 months with p = 0.004 in terms of immunophenotype HER-2 (positive) vs HER-2 (positive)/ HR (hormonal receptor)= were 68.4 months vs 63.3 months p = 0.59 Conclusion: Although the main weakness of this study is that it is a retrospective trial, it is striking that several treatment options have been provided to stage I, however it must be analyzed that 10 patients were treated only with trastuzumab, reaching a survival of 70 months, while the remaining 12 patients were divided into several treatment options, although the AC scheme reports 76 months of survival corresponds to a single patient, for this reason is necessary a institucional or national guideline for treatment cancer in Ecuador.